News from Mayo Clinic

June 16, 2016
References
  1. Kaewlai R, et al. Nephrogenic systemic fibrosis. American Journal of Roentgenology. 2012;199:W17.
  2. Galan A, et al. Nephrogenic systemic fibrosis. In: Treatment of Skin Disease: Comprehensive Therapeutic Strategies. 4th ed. Philadelphia, Pa.: Elsevier Limited; 2014. http://www.clinicalkey.com. Accessed March 9, 2016.
  3. Questions and answers on gadolinium-based contrast agents. U.S. Food and Drug Administration. http://www.fda.gov/Drugs/DrugSafety/DrugSafetyNewsletter/ucm142889.htm. Accessed March 9, 2016.
  4. Nephrogenic systemic fibrosis. National Organization for Rare Disorders. http://rarediseases.org/rare-diseases/nephrogenic-systemic-fibrosis/. Accessed March 9, 2016.
  5. Thomsen HS, et al. Nephrogenic systemic fibrosis and gadolinium-based contrast media: Updated ESUR Contrast Medium Safety Committee guidelines. European Radiology. 2013;23:307.
  6. Ferri FF. Nephrogenic systemic fibrosis. In: Ferri's Clinical Advisor 2016. Philadelphia, Pa.: Mosby Elsevier; 2016. https://www.clinicalkey.com. Accessed March 9, 2016.
  7. Miskulin D, et al. Nephrogenic systemic fibrosis/nephrogenic fibrosing dermopathy in advanced renal failure. http://www.uptodate.com/home. Accessed March 9, 2016.
  8. Leung N (expert opinion). Mayo Clinic, Rochester, Minn. March 15, 2016.